Research Analysts Issue Forecasts for Zoetis Inc’s Q3 2019 Earnings (NYSE:ZTS)

Zoetis Inc (NYSE:ZTS) – Equities research analysts at William Blair decreased their Q3 2019 earnings per share (EPS) estimates for Zoetis in a research report issued to clients and investors on Thursday, July 11th. William Blair analyst J. Kreger now forecasts that the company will earn $0.87 per share for the quarter, down from their prior forecast of $0.88. William Blair also issued estimates for Zoetis’ FY2019 earnings at $3.45 EPS, FY2020 earnings at $3.78 EPS and FY2023 earnings at $5.04 EPS.

Several other equities research analysts have also commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $130.00 price objective (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Craig Hallum boosted their price objective on Zoetis from $114.00 to $132.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Gabelli reiterated a “buy” rating on shares of Flushing Financial in a research note on Thursday, May 2nd. Guggenheim restated a “buy” rating and issued a $95.00 price target (up from $90.00) on shares of VF in a research report on Thursday, May 23rd. Finally, Bank of America set a $221.00 price target on Constellation Brands and gave the company a “buy” rating in a research report on Monday, July 1st. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $110.40.

NYSE:ZTS opened at $113.31 on Friday. Zoetis has a 12 month low of $78.90 and a 12 month high of $116.47. The business’s 50 day moving average price is $110.16. The company has a current ratio of 4.05, a quick ratio of 2.79 and a debt-to-equity ratio of 2.84. The stock has a market cap of $54.73 billion, a price-to-earnings ratio of 36.20, a P/E/G ratio of 3.12 and a beta of 0.91.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.88 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.09. Zoetis had a return on equity of 73.66% and a net margin of 23.47%. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same period in the previous year, the business earned $0.75 EPS. Zoetis’s quarterly revenue was up 6.5% on a year-over-year basis.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZTS. Resources Investment Advisors Inc. acquired a new position in Zoetis in the fourth quarter valued at approximately $31,000. Commonwealth Bank of Australia lifted its holdings in Zoetis by 19.7% in the fourth quarter. Commonwealth Bank of Australia now owns 18,891 shares of the company’s stock valued at $1,611,000 after acquiring an additional 3,114 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Zoetis by 2.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,425,455 shares of the company’s stock valued at $121,929,000 after acquiring an additional 39,319 shares during the last quarter. Berman Capital Advisors LLC acquired a new position in Zoetis in the fourth quarter valued at approximately $26,000. Finally, Gideon Capital Advisors Inc. acquired a new position in Zoetis in the fourth quarter valued at approximately $233,000. Hedge funds and other institutional investors own 90.17% of the company’s stock.

In related news, Director Willie M. Reed sold 1,900 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $110.58, for a total value of $210,102.00. Following the transaction, the director now directly owns 2,816 shares in the company, valued at $311,393.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Roxanne Lagano sold 29,453 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $101.65, for a total value of $2,993,897.45. Following the completion of the transaction, the insider now owns 58,180 shares in the company, valued at $5,913,997. The disclosure for this sale can be found here. Insiders sold 76,614 shares of company stock valued at $7,893,115 over the last 90 days. Company insiders own 0.29% of the company’s stock.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 19th will be given a $0.164 dividend. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.58%. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: How To Calculate Debt-to-Equity Ratio

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.